ChromaDex [CDXC] vs Vera Therapeutics [VERA] Detailed Stock Comparison
ChromaDex
NASDAQ
Loading...
Vera Therapeutics
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: ChromaDex wins in 7 metrics, Vera Therapeutics wins in 5 metrics, with 0 ties. ChromaDex appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | ChromaDex | Vera Therapeutics | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 71.55 | -10.57 | Vera Therapeutics |
| Price-to-Book Ratio | 13.72 | 3.92 | Vera Therapeutics |
| Debt-to-Equity Ratio | 0.06 | 16.56 | ChromaDex |
| PEG Ratio | -0.09 | -0.11 | Vera Therapeutics |
| EV/EBITDA | 77.40 | -5.79 | Vera Therapeutics |
| Profit Margin (TTM) | 61.84% | 0.00% | ChromaDex |
| Operating Margin (TTM) | 7.76% | 0.00% | ChromaDex |
| EBITDA Margin (TTM) | 7.76% | N/A | N/A |
| Return on Equity | 18.55% | -54.84% | ChromaDex |
| Return on Assets (TTM) | 12.52% | -30.24% | ChromaDex |
| Free Cash Flow (TTM) | $11.95M | $-135.65M | ChromaDex |
| 1-Year Return | 156.84% | -28.53% | ChromaDex |
| Price-to-Sales Ratio (TTM) | 7.58 | N/A | N/A |
| Enterprise Value | $712.88M | $1.37B | Vera Therapeutics |
| EV/Revenue Ratio | 7.16 | N/A | N/A |
| Gross Profit Margin (TTM) | 63.42% | N/A | N/A |
| Revenue per Share (TTM) | N/A | $0 | N/A |
| Earnings per Share (Diluted) | N/A | $-3.68 | N/A |
| Beta (Stock Volatility) | N/A | 1.16 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
ChromaDex vs Vera Therapeutics Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| ChromaDex | 3.72% | -1.01% | -2.79% | -29.38% | 27.58% | 78.10% |
| Vera Therapeutics | 1.39% | 8.27% | 29.10% | 23.42% | 23.74% | -30.83% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| ChromaDex | 156.84% | 693.50% | 148.35% | 160.27% | 140.99% | -18.67% |
| Vera Therapeutics | -28.53% | 46.24% | 153.83% | 153.83% | 153.83% | 153.83% |
News Based Sentiment: ChromaDex vs Vera Therapeutics
ChromaDex
News based Sentiment: POSITIVE
Niagen Bioscience demonstrated strong financial performance in Q2 2025, with significant revenue growth and a return to profitability. The completion of the rebranding to Niagen Bioscience and continued high Earnings Quality Ranking further strengthen the investment case, making this a positive month for the company and its investors.
Vera Therapeutics
News based Sentiment: POSITIVE
The combination of a new institutional investment from Perigon Wealth Management and a five-day stock gain streak signals a positive shift for Vera Therapeutics. While not a transformative event, it suggests increasing investor confidence and potential for future growth, making it a noteworthy development for investors.
Performance & Financial Health Analysis: ChromaDex vs Vera Therapeutics
| Metric | CDXC | VERA |
|---|---|---|
| Market Information | ||
| Market Cap | $754.74M | $1.91B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 858,318 | 1,631,290 |
| 90 Day Avg. Volume | 848,086 | 1,793,945 |
| Last Close | $9.76 | $29.19 |
| 52 Week Range | $3.18 - $14.69 | $18.53 - $51.61 |
| % from 52W High | -33.56% | -43.44% |
| All-Time High | $23.66 (Feb 22, 2021) | $51.61 (Nov 11, 2024) |
| % from All-Time High | -58.75% | -43.44% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | N/A |
| Quarterly Earnings Growth | 0.38% | N/A |
| Financial Health | ||
| Profit Margin (TTM) | 0.62% | 0.00% |
| Operating Margin (TTM) | 0.08% | 0.00% |
| Return on Equity (TTM) | 0.19% | -0.55% |
| Debt to Equity (MRQ) | 0.06 | 16.56 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $0.71 | $7.34 |
| Cash per Share (MRQ) | N/A | $8.72 |
| Operating Cash Flow (TTM) | $12.22M | $-185,271,008 |
| Levered Free Cash Flow (TTM) | $8.55M | $-111,946,496 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: ChromaDex vs Vera Therapeutics
| Metric | CDXC | VERA |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 71.55 | -10.57 |
| Forward P/E | 65.58 | -9.25 |
| PEG Ratio | -0.09 | -0.11 |
| Price to Sales (TTM) | 7.58 | N/A |
| Price to Book (MRQ) | 13.72 | 3.92 |
| Market Capitalization | ||
| Market Capitalization | $754.74M | $1.91B |
| Enterprise Value | $712.88M | $1.37B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 7.16 | N/A |
| Enterprise to EBITDA | 77.40 | -5.79 |
| Risk & Other Metrics | ||
| Beta | N/A | 1.16 |
| Book Value per Share (MRQ) | $0.71 | $7.34 |
Financial Statements Comparison: ChromaDex vs Vera Therapeutics
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CDXC | VERA |
|---|---|---|
| Revenue/Sales | $29.13M | $0 |
| Cost of Goods Sold | $10.93M | N/A |
| Gross Profit | $18.20M | N/A |
| Research & Development | $1.32M | $41.28M |
| Operating Income (EBIT) | $7.11M | $-57.19M |
| EBITDA | $7.47M | $-49.82M |
| Pre-Tax Income | $7.48M | $-51.69M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | $7.18M | $-51.69M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CDXC | VERA |
|---|---|---|
| Cash & Equivalents | $44.51M | $55.09M |
| Total Current Assets | $64.10M | $606.08M |
| Total Current Liabilities | $17.95M | $21.89M |
| Long-Term Debt | $1.66M | $53.27M |
| Total Shareholders Equity | $46.09M | $535.00M |
| Retained Earnings | $-181.91M | $-512.94M |
| Property, Plant & Equipment | $6.02M | $1.06M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CDXC | VERA |
|---|---|---|
| Operating Cash Flow | $7.95M | $-41.22M |
| Capital Expenditures | $-32,000 | $-187,000 |
| Free Cash Flow | $7.85M | $-54.59M |
| Debt Repayment | $-3,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | CDXC | VERA |
|---|---|---|
| Shares Short | N/A | 9.36M |
| Short Ratio | N/A | 4.91 |
| Short % of Float | N/A | 0.17% |
| Average Daily Volume (10 Day) | 858,318 | 1,631,290 |
| Average Daily Volume (90 Day) | 848,086 | 1,793,945 |
| Shares Outstanding | 77.33M | 63.56M |
| Float Shares | N/A | 42.92M |
| % Held by Insiders | N/A | 0.04% |
| % Held by Institutions | N/A | 1.10% |
Dividend Analysis & Yield Comparison: ChromaDex vs Vera Therapeutics
| Metric | CDXC | VERA |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |